Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Puma Biotechnology (PBYI) Operating Expenses: 2017-2025

Historic Operating Expenses for Puma Biotechnology (PBYI) over the last 8 years, with Sep 2025 value amounting to $44.9 million.

  • Puma Biotechnology's Operating Expenses fell 23.20% to $44.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $178.4 million, marking a year-over-year decrease of 15.50%. This contributed to the annual value of $199.5 million for FY2024, which is 1.72% down from last year.
  • Latest data reveals that Puma Biotechnology reported Operating Expenses of $44.9 million as of Q3 2025, which was down 1.96% from $45.8 million recorded in Q2 2025.
  • In the past 5 years, Puma Biotechnology's Operating Expenses registered a high of $78.0 million during Q1 2021, and its lowest value of $42.0 million during Q1 2025.
  • For the 3-year period, Puma Biotechnology's Operating Expenses averaged around $48.7 million, with its median value being $47.5 million (2023).
  • In the last 5 years, Puma Biotechnology's Operating Expenses tumbled by 40.42% in 2022 and then increased by 23.00% in 2024.
  • Over the past 5 years, Puma Biotechnology's Operating Expenses (Quarterly) stood at $48.5 million in 2021, then increased by 14.70% to $55.7 million in 2022, then grew by 3.09% to $57.4 million in 2023, then decreased by 20.33% to $45.7 million in 2024, then decreased by 23.20% to $44.9 million in 2025.
  • Its last three reported values are $44.9 million in Q3 2025, $45.8 million for Q2 2025, and $42.0 million during Q1 2025.